Abstract 792P
Background
Gastric-type mucinous carcinoma (GAS) is a novel variant of mucinous carcinoma of the uterine cervix. We previously reported that GAS showed aggressive behavior with ominous histopathological predictors and decreased survival. GAS is a distinct entity that should be distinguished from usual-type endocervical adenocarcinoma (UEA). In Japan, postoperative adjuvant therapy for cervical cancer includes not only radiation therapy (RT) or concurrent chemoradiotherapy (CCRT), but also chemotherapy in many cases. However, there are no reports analyzing adjuvant therapy for GAS. In this study, we investigated the efficacy of adjuvant therapy for GAS.
Methods
This was a preplanned secondary analysis of the dataset of a previous nationwide, retrospective observational study. Patients were enrolled by the Gynecologic Cancer Study Group of the Japan Clinical Oncology Group after procurement of ethical approval from each institutional review board. The study population comprised women with stage I to II GAS who underwent surgery between 2000 and 2009. The progression-free survival (PFS) and overall survival (OS) of patients who received no adjuvant therapy, RT, CCRT, or chemotherapy were statistically compared with the Kaplan-Meier method.
Results
A total of 102 patients were enrolled and analyzed. The patients were classified as low-risk (17 patients), intermediate-risk (37 patients), and high-risk (48 patients) based on the risk of postoperative cervical cancer recurrence. In the intermediate-risk group, median survival could not be measured in terms of PFS and OS due to the absence of events, but the no adjuvant and RT groups tended to have a better prognosis. In contrast, in the high-risk group, there was a trend toward better PFS and OS in the RT group than in the CCRT and chemotherapy groups.
Conclusions
The prognosis of GAS was once again confirmed to be poor, even in cases of early-stage cancer and surgical resection. Chemotherapy strategy, including CCRT as a postoperative adjuvant therapy, tended to have a poor prognosis.
Clinical trial identification
UMIN000007987.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.